As the innovation process of pharmaceuticals is a long, risky and very costly business, economists typically emphasise lack of profit incentives and small market size as the most important obstacles to child-related innovative activity. Moreover, there are ethical concerns because children are...

This paper considers the U.S. Small Business Innovation Research (SBIR) program as a policy fostering academic entrepreneurship. We highlight two main characteristics of the program that make it attractive as an entrepreneurship policy : early-stage financing and scientist involvement in...

Is there a trade-off of scholarly research productivity when faculty members found or join for-profit firms? This paper offers an empirical examination of this question for a subpopulation of biomedical academic scientists who received research funding from the U.S. National Institutes of Health...

Als Molekulare Diagnostik werden alle diagnostischen Methoden verstanden, die auf der Grundlage molekularer oder biochemischer Analysen in vivo (im lebenden Organismus) und in vitro (im Versuch, außerhalb des Organismus) gemacht werden. Die nachfolgende Studie beschränkt sich auf die in vitro...

Das Gesundheitssystem gerät durch steigende Ausgaben in der Gesetzlichen Krankenversicherung zunehmend unter Druck. Welche Rolle spielt dabei der medizinische Fortschritt?

Focussing on China's health biotech clusters the study explores the anatomy of interaction in as well as between various clusters. While the literature has identified the existence of a dense network of durable interactions among firms and between firms and academia at a particular location as...

In der sich vollziehenden Transformation des Systems zur Absicherung von Krankheitsrisiken in der Bundesrepublik bleibt eine Institution weitgehend ausgeklammert: der Medizinische Dienst der Krankenversicherung (MDK). Dieser Dienst hat die Funktion einer unabhängigen Begutachtungs- und...